Niagen Bioscience (NAGE) CFO reports direct and indirect share buys

Rhea-AI Filing Summary

Niagen Bioscience, Inc. (NAGE) reported insider share purchases by its Chief Financial Officer on a Form 4. On 11/14/2025, the CFO bought 4,464.962 shares of common stock in a direct transaction at a weighted average price of $6.81, with individual trade prices ranging from $6.7975 to $6.82. After this transaction, the CFO directly owned 7,372.159 shares of Niagen Bioscience common stock. On the same date, the CFO’s spouse acquired 2,220.443 shares at $6.85, which are reported as indirectly owned, bringing the indirect beneficial ownership to 2,220.443 shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pamir Ozan

(Last) (First) (Middle)

10900 WILSHIRE BLVD. SUITE 600

(Street)

LOS ANGELES CA 90024

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Niagen Bioscience, Inc. [ NAGE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/14/2025		P		4,464.962	A	$6.81(1)	7,372.159	D
Common Stock	11/14/2025		P		2,220.443	A	$6.85	2,220.443	I	The reported securities are held by the reporting person's spouse.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The weighted average purchase price for the transaction reported was $6.81, and the range of prices were between $6.7975 and $6.82, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range above will be provided.

Remarks:

	/s/ Jeong James Lee, Attorney-in-Fact	11/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Niagen Bioscience (NAGE) report in this Form 4 filing?

The filing reports that the Chief Financial Officer of Niagen Bioscience, Inc. (NAGE) purchased common stock on 11/14/2025, with both direct and indirect holdings disclosed.

How many Niagen Bioscience (NAGE) shares did the CFO buy directly?

The CFO directly purchased 4,464.962 shares of Niagen Bioscience common stock on 11/14/2025 at a weighted average price of $6.81 per share.

What is the CFO’s total direct ownership in Niagen Bioscience after the transactions?

Following the reported transaction, the CFO beneficially owned 7,372.159 shares of Niagen Bioscience common stock in a direct capacity.

Were any Niagen Bioscience (NAGE) shares acquired indirectly by the CFO’s spouse?

Yes. The filing states that 2,220.443 shares of common stock were acquired at $6.85 per share and are held by the reporting person’s spouse, reported as indirect beneficial ownership.

What was the price range for the CFO’s Niagen Bioscience share purchases?

The explanation notes that the weighted average purchase price was $6.81, with individual trades executed between $6.7975 and $6.82, inclusive.

Who signed the Niagen Bioscience (NAGE) Form 4 and on what date?

The Form 4 was signed by /s/ Jeong James Lee, Attorney-in-Fact on 11/17/2025, acting on behalf of the reporting person.